1,149
Participants
Start Date
March 31, 2015
Primary Completion Date
February 28, 2017
Study Completion Date
October 31, 2020
D/C/F/TAF
Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.
Boosted Protease Inhibitor (bPI)
Boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) as per current treatment regimen.
FTC/TDF
Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).
Phoenix
Bakersfield
Beverly Hills
Long Beach
Los Angeles
San Diego
San Francisco
Washington D.C.
Fort Lauderdale
Ft. Pierce
Orlando
West Palm Beach
Atlanta
Savannah
Chicago
Boston
Springfield
Berkley
Detroit
Minneapolis
Kansas City
St Louis
Hillsborough
Newark
Somers Point
Santa Fe
New York
Chapel Hill
Winston-Salem
Cincinnati
Philadelphia
Providence
Austin
Dallas
Fort Worth
Houston
Longview
Seattle
Antwerp
Brussels
Ghent
Leuven
Liège
Edmonton
Vancouver
Toronto
Montreal
Le Kremlin-Bicêtre
Lyon
Marseille
Montpellier
Nantes
Paris
Strasbourg
Tourcoing
Bydgoszcz
Chorzów
Lodz
Warsaw
Wroclaw
San Juan
Alicante
Badalona
Barcelona
Córdoba
Donostia / San Sebastian
Elche
Madrid
Seville
Valencia
Gothenburg
Malmo
Stockholm
Basel
Bern
Zurich
Brighton
London
Manchester
Janssen R&D Ireland
INDUSTRY